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ABSTRACT  Silicosis patients（SIL）develop respiratory fibrosis caused by inhaled silica 
particles, and autoimmune disorders such as rheumatoid arthritis and systemic sclerosis（SSc）. 
Silica is known as one of the most important environmental factors leading to the development 
of SSc.  Various soluble cytokines such as interleukin (IL)-2 receptor (sIL-2R) and CD155/CD40 
ligand（sCD40L）, soluble endoglin, von Willebrand factor antigen（vWFAg）, and soluble Fas 
show elevated levels in SSc.  Among these parameters, sCD40L was targeted as a possible 
subclinical parameter in SIL.  Factor analysis using the data of ten SIL showed that sCD40L 
was correlated only with sFas, whereas sCD40L formed a factor showing immunological 
alteration（without respiratory progression）with several other immunopathological parameters 
such as the titer of anti-nuclear antibodies（ANA）and immunoglobulin（Ig）G.  However, 
sCD40L assays using ten healthy donors（HD）, ten SIL and ten SSc patients did not show a 
higher level for SSc, although ANA and sIL-2R levels were correlated with a progressive ranking 
（HD as 1, SIL as 2, SSc as 3）.  The overall results suggest that sCD40L in SSc should be 
examined in regard to the state of the disease.  At present, sCD40L is not considered a good 
indicator of subclinical disturbance in SIL.
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INTRODUCTION
   Silica is known to cause pulmonary fibrosis and 
autoimmune diseases such as rheumatoid arthritis 
(RA), systemic sclerosis (SSc) and systemic 
lupus erythematosus (SLE)１，２）.  RA complicated 
with silicosis (SIL) is well known as Caplan's 
syndrome３）.  SSc is caused by some environmental 
substances such as silica and vinyl chloride４，５）. 
These substances are also associated with other 
autoimmune disorders such as systemic vasculitis 
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and pemphigus vulgaris complicated with SIL６，７）. 
Moreover, various autoantibodies have been 
detected in the sera of SIL without any clinical 
manifestations of autoimmune disorders, i.e., 
antibodies against desmoglein, Fas, and caspase 8 
molecules８－10）.
   On the other hand, there have been reports of 
many molecules related to immunoreactions such as 
soluble interleukin (IL)-2 receptor (sIL-2R), soluble 
CD40 ligand (sCD40L), soluble endoglin, von 
Willebrand factor antigen (vWFAg), and soluble 
Fas11－17）in SSc.
   We have been investigating the possibility of using 
several serum markers as preclinical parameters 
for SIL with immunopathological disturbances 
and mechanisms involved in silica-induced 
dysregulation of autoimmunity18－22）.  In particular, 
the following aspects of Fas and Fas-related 
molecules have been investigated: (i) elevated 
levels of serum-soluble Fas (sFas) in SIL23）, (ii) 
excessive expression of soluble rather than wild-
type Fas genes in peripheral blood mononuclear 
cells (PBMCs) from SIL24）, (iii) excessive detection 
of variant messages of Fas transcripts and sFas25）, 
(iv) excessive expression of decoy receptor 3 (DcR3) 
in PBMCs from SIL26）, (v) reduced expression of 
intracellular anti-apoptotic molecules related to Fas-
mediated apoptosis in PBMCs from SIL27，28）, and 
(vi) detection of functional (apoptosis inducible) 
serum anti-Fas autoantibody in SIL９）.  These Fas-
related parameters were isolated as immunological 
markers from other respiratory clinical parameters 
such as percent vital capacity (%VC), profusion rate 
(PR), which is a category pertaining to radiological 
findings according to the International Labor Office 
(ILO) guideline29）, and the percentage of forced 
expiratory volume in 1 second (FEV1.0%)30）.
   As mentioned above, sCD40L has been reported 
as a serum marker for SSc.  The CD40/CD154 
(CD40L) interaction is important for activation 
of humoral and cellular responses31－39）.  CD40 
and its ligand belong to the tumor-necrosis factor 
(TNF) receptor superfamily, and both molecules are 
transmembrane glycoproteins.  However, both can 
be cleaved easily by proteolytic activity.  Activated 
T cells express CD40L and interact with CD40 on 
the surface of B cells.  During this reaction, the 
cleavage of CD40L occurs and a soluble form of 
CD40L with biological activities is produced.  The 
sCD40L can bind with CD40 and enhances the 
reaction.  Thus, it appears that sCD40L reflects the 
degree of T cell activation in autoimmune diseases, 
and elevated serum sCD40L levels in SSc have been 
reported11－17）.
   We recently reported that sIL-2R is a marker for 
immunopathological disturbance in SIL without 
clinical manifestation of autoimmune diseases40）. 
We then considered the possibility that sCD40L is 
also a clinical parameter for immunopathological 
disturbance in SIL.  In this article, details of the 
measurement of sCD40L in HD, SIL and SSc 
patients are presented and the clinical role of 
sCD40L in SIL is discussed.
SUBJECTS AND METHODS
Subjects and clinical parameters
   All subjects were Japanese.  Ten HD (age (mean±
standard deviation (SD)) = 60.6±5.8, male:female 
= 6:4), ten SIL (age = 74.4±8.7, M:F=7:3) and ten 
SSc patients (age = 50.8±13.3, M:F=2:8) were 
investigated in this study.  All SIL were brickyard 
workers in Bizen City, Okayama Prefecture, Japan, 
and were monitored at Kusaka Hospital.  The 
amount of free silica inhaled by these patients 
was estimated as high as 40 to 60% as determined 
from their work environment.  The subjects were 
diagnosed with pneumoconiosis according to the 
ILO 2000 guideline29）.  They showed no clinical 
symptoms of autoimmune diseases, including 
sclerotic skin, Raynaud's phenomenon, facial 
erythema or arthralgia.  The SSc patients were 
monitored by the Department of Dermatology, 
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Kawasaki Medical School Hospital, Japan. Eight 
of the ten SSc patients were administered oral 
corticosteroids.  Heparinized peripheral blood 
was drawn from the cubital vein from all subjects. 
Serum samples from all subjects were analyzed for 
anti-nuclear antibodies (ANA) using the Enzyme-
Linked ImmunoSorbent Assay (ELISA)-based 
MESACUP ANA Test Kit (MBL Co. Ltd., Nagoya, 
Japan), serum immunoglobulin (Ig) G concentration, 
complement (C) 4, IL-2 concentration, sFas, titer of 
Anti-Scl-70 antibody (Ab), titer of anti-centromere 
(CM) Ab, sIL-2R and sCD40L (all parameters were 
measured using individual ELISA kits, MBL).  The 
ANA titer performed in this study included several 
recombinant proteins such as RNP, SS-A/Ro, SS-B/
La, Scl-70, Jo-1 and Ribosomal P in vitro transcribed 
U1 RNA and CENP-B protein, and purified antigens 
(Sm, SS-A/Ro, Scl-70m Histone and DNA).  All 
measurements were performed according to the 
manufacturer's instructions, and ANA, anti-Scl-70 
and anti-CM Abs measurements are presented 
as index values.  Clinical data (exposure years, 
FEV1.0%, %VC, PR (numbered according to the 
ILO guideline, 1 to 4) and subjective dyspnea 
(numbered as 1: slight, 2: mild, 3: moderate, and 4: 
severe, according to the Hugh-Jones classification) 
were provided by Kusaka Hospital.  All specimens 
were taken only when informed consent had been 
obtained.  This study was approved by the Ethics 
Committees of Kawasaki Medical School and 
Kusaka Hospital.
Statistical analysis
   Correlations in SIL for all respiratory and 
immunological parameters with age were initially 
analyzed.  Factor analysis was performed to 
determine clinical parameters related to the 
other parameters.  Parameters showing factor 
loading values greater than±0.4 were regarded 
as meaningful for factor configuration.  The data 
can therefore be used to determine (i) parameters 
that contribute to the factor, (ii) how the values of 
contributing parameters (values near 1.0 are strongly 
related to the formation of the factor, whereas minus 
(or plus) values can be interpreted as reflecting a 
lower (or higher) contribution by this parameter) 
explain the tendency of the factor, and (iii) the 
contribution ratio of factors30）.
   To determine whether the immunological 
parameters (including C4, Ig G, IL-2, ANA, anti-
Scl-70 Ab, anti-CM Ab, sIL-2R and sCD40L) were 
related to the progression of altered autoimmunity, 
differences between HD, SIL and SSc patients 
were analyzed for each parameter. The statistical 
differences among the three groups were analyzed 
using the Mann-Whitney test. In addition, after 
defining HD = 1, SIL = 2 and SSc =3 as metric 
variables for immunological progression, the 
correlation between these numbers and each 
parameter value was analyzed.  All statistical 
analyses were performed using StatView software 
version 5.0 (SAS Institute Inc. Cary, NC, USA) and 
StatFlex version 5.0 software for Windows (Artech 
Co. Ltd., Osaka, Japan), which yield results that are 
compatible with SPSS software.
RESULTS
Correlation of clinical parameters in SIL
   As shown in Table 1, reciprocal correlations 
among all clinical parameters investigated in this 
study in SIL were analyzed.  First of all, age was 
related negatively with %VC and positively with 
IL-2.  These findings may reflect the physiological 
age-related changes of both parameters.  Among 
the respiratory parameters, there was a reasonable 
negat ive correlat ion between dyspnea and 
FEV1.0%.  On the other hand, analysis of assumed 
immunological parameters revealed that Ig G was 
correlated positively with ANA, sIL-2R, anti-Scl-70 
Ab and anti-CM Ab, and negatively with C4.  The 
results also showed a negative correlation between 
C4 and ANA, and positive correlations between 
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Table 1.　Correlation between various clinical parameters among silicosis patients
Age
(years)
Duration
of
exposure
(years)
PR
(numbered)
Subjective
Dyspnea
(numbered)
%VC
(%)
FEV1.0
% (%)
Ig G
(mg/dl)
C4
(mg/dl)
ANA
(Index
Value)
IL-2
(pg/ml)
sIL-2R
(pg/ml)
sFas
(ng/ml)
Anti-Scl-
70 Ab
(Index
Value)
Anti-CM
Ab
(Index
Value)
sCD4oL
(pg/ml)
Age (years) .061
.8813
-.190
.3367
.385
.2828
-.695
.0233
-.407
.2534
.289
.4304
-.109
.7721
.609
.0612
.652
.0392
.324
.3739
.604
.0868
-.161
.6684
.333
.9601
.600
.0669
Duration of 
exposure (years)
.500
.1788
-.158
.6960
.248
.5352
-.238
.5529
-.135
.7396
-.055
.8921
-.148
.7145
-.140
.7308
-.154
.7046
.271
.5339
.095
.8163
-.163
.6870
-.055
.8919
PR (numbered) .379
.2908
-.116
.7579
-.028
.9420
-.212
.6588
.679
.0287
-.503
.1434
.027
.9437
-.133
.7233
-.401
.2979
-.228
.5387
.131
.7280
.081
.8301
Subjective Dysp
nea (numbered)
-.473
.1742
-.753
.0096
-.167
.6553
.316
.3865
-.040
.9162
.204
.5848
-.058
.8771
-.184
.6476
-.288
.4333
.002
.9541
.019
.9595
%VC (%) -.695
.0233
.306
.4033
-.107
.7760
-.185
.6203
-.325
.3723
-.706
.0199
-.122
.7464
-.204
.6126
.075
.8427
-.141
.7080
-.295
.4205
FEV1.0% (%) -.753
.0096
.455
.1934
-.171
.6480
.038
.9201
-.348
.3367
.391
.2750
.079
.8468
.460
.1885
.384
.2846
.146
.6978
Ig G (mg.dl) -.658
.0369
.766
.0076
.238
.5204
.988
<.0001
.407
.2901
.794
.0042
.823
.0020
.151
.6870
C4 (mg/dl) .679
.0287
-.658
.0369
-.775
.0063
-.173
.6435
-.586
.0757
.124
.7594
-.604
.0640
-.203
.5858
.266
.4709
ANA
(Index Value)
.766
.0076
-.775
.0063
.538
.1112
.745
.0110
.526
.1523
.463
.1844
.518
.1287
.152
.6854
IL-2 (pg/ml) .652
.0392
-.706
.0199
.218
.5569
.081
.8429
.123
.7427
.102
.7875
.004
.9908[
sIL-2R (pg/ml) .988
<.0001
.745
.0110
.418
.2753
.750
.0100
.886
.0002
.203
.5857
sFas (ng/ml) -.337
.3899
.472
.2037
.715
.0281
Anti-Scl70 Ab
(Index Value)
.794
.0042
.750
.0100
.529
.1189
-.376
.2951
     Anti-CM Ab  
(Index Value)
.823
.0020
.886
.0002
.464
.1840
sCD4oL (pg/ml) .715
.0281
In each cell in the upper-right half of the table, the upper value represents ρ and the lower entry is the p value. Significant correlations are 
listed in the lower-left half of the table. Correlations showing p < .01 are presented in bold and significant (p<.05) correlations are shaded in 
gray. 
sIL-2R and ANA, anti-Scl-70 Ab, or anti-CM Ab. 
These correlations are reasonable and it is thought 
that several immunopathological parameters showed 
similar directions in the development of disturbance. 
Results concerning sCD40L showed that only the 
sFas level was positively correlated.  Thus, sCD40L 
may not be a strong marker of immunopathological 
progression in SIL.  In addition, a positive 
correlation between C4 and PR and a negative 
correlation between IL-2 and %VC were observed. 
Although the latter may be interrupted by age, the 
former was not interrupted to a considerable degree. 
However, this finding may be coincidental.
Factor analysis
   Factor analysis was performed to determine 
clinical parameters related to the other parameters. 
Parameters showing factor loading values greater 
than ± 0.4 were regarded as meaningful for factor 
configuration and are shaded in gray in Table2. 
The data can therefore be used to determine (i) 
parameters that contribute to the factor, (ii) how the 
values of contributing parameters (values near 1.0 
are strongly related to the formation of the factor, 
whereas minus (or plus) values can be interpreted 
as reflecting a lower (or higher) contribution by this 
parameter) explain the tendency of the factor, and 
(iii) the contribution ratio of factors30）.
   According to results shown in Table 2, factor 1 
consists of several respiratory variables (FEV1.0, 
%VC and subject ive dyspnea)  and several 
immunological variables (sFas, IL-2, ANA and 
anti-Scl-70  Ab).  FEV1 .0 ,  %VC and v25/Ht 
having minus-loading values were recognized as 
representing a worse respiratory function.  Similarly, 
dyspnea with a plus-loading value indicated a 
worse respiratory disease status.  In regard to 
immunological variables, the plus-loading values 
of IL-2 and ANA are thought to represent a worse 
immunological status, whereas minus values of Scl-
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Table 2.　Factor analysis
Parameter Factor 1 Factor 2 Factor 3
Age (years) 0.97916 0.27601 0.06296
Exposure Years (years) -0.05027 -0.01221 0.38142
FEV1.0% (%) -0.62279 0.49622 0.20688
%VC -0.70821 -0.14560 0.20396
PR (Radiological Classiﬁcation) -0.16950 0.12272 -0.89780
Subjective Dyspnea (numbered) 0.49768 -0.23287 -0.71221
Serum Ig G (log) (mg/d) -0.20556 0.90564 0.06658
C4 (mg/dl) 0.00646 0.43799 -0.73200
Serum-soluble Fas(ng/ml) 0.42936 0.57232 0.36309
Serum IL-2 (pg/ml) 0.88604 -0.34320 0.07629
Serum-soluble IL-2R (pg/ml) -0.05009 0.95234 -0.29647
Serum ANA titer (index) 0.74471 0.00927 0.47323
Serum Anti-Scl-70 Ab (index） -0.78648 -0.09121 0.13032
Serum Anti-Centromere-Ab (index) 0.01392 0.85914 -0.40600
sCD40L (ng/ml) 0.39918 0.83605 -0.00505
Contribution Ratio 29.82693 28.15242 18.12474
Factor analysis was performed to determine clinical parameters related to the other parameters.  Parameters showing factor loading values 
greater than ± 0.4 were regarded as meaningful for factor configuration and are shaded in gray.  The data can therefore be used to determine 
(i) parameters that contribute to the factor, (ii) how the values of contributing parameters (values near 1.0 are strongly related to the formation 
of the factor, whereas minus (or plus) values can be interpreted as reflecting a lower (or higher) contribution by this parameter) explain the 
tendency of the factor, and (iii) the contribution ratio of factors.  According to the analysis shown here, factor 1 consists of several respiratory 
variables (FEV1.0, %VC and subjective dyspnea) and several immunological variables (sFas, IL-2, ANA and anti-Scl-70 Ab).  FEV1.0, 
%VC and v25/Ht parameters with minus values were recognized as representing a worse respiratory function.  Similarly, dyspnea with a 
plus-loading value indicated a worse respiratory disease status.  In regard to immunological variables, plus-loading values of IL-2 and ANA 
are thought to represent a worse immunological status, whereas minus values of Scl-70 do not.  Overall, factor 1 should be interpreted as 
representing patients having a tendency for both a respiratory and immunological worse status, with 30% of patients possessing this tendency.  
70 do not.  Overall, factor 1 should be interpreted 
as representing patients having a tendency for both 
a respiratory and immunological worse status, with 
30% of patients possessing this tendency. 
   The sCD40L parameter was involved in the 
formation of factor 2.  This factor consisted mostly 
of immunological parameters such as Ig G, C4, sFas, 
sIL-2R and anti-CM Ab, with a weak contribution 
by FEV1.0%.  As the plus- but weak loading values 
of C4 and FEV1.0% were considered unimportant, 
this factor can be viewed as an immunological 
factor.  The patients (28%) associated in this 
fac tor  are  considered to  have progress ive 
immunopathology without the development of 
respiratory alterations.  It is important that sCD40L 
was involved in this factor because this supports 
the assertion that sCD40L in SIL also represents an 
immunopathological marker.
   Factor 3 was associated with better PR and 
dyspnea, and worse C4 in 18% of patients.  It 
is difficult to interpret this factor; however, 
18% of  pa t i en t s  d id  no t  show any  worse 
respiratory progression with slight disturbance of 
immunopathology. 
Statistical differences between several immunopathological 
parameters in HD, SIL and SSc patients
   ANA, Ig G, sIL-2R and sCD40L values were 
compared among HD, SIL and SSc patients.  As 
shown in Fig. 1, the titer of ANA in HD was lower 
than that of SIL and SSc.  The titer of ANA in 
SIL was also lower than that of SSc.  Thus, ANA 
increased significantly from HD to SIL to SSc. 
The levels of Ig G and sIL-2R in SSc were higher 
than those of HD.  However, levels in SIL did not 
show any differences from those of HD or SSc. 
Surprisingly, sCD40L in SSc was lower than that of 
HD or SIL.  These results are the reverse of those 
showing higher levels of sCD40L in SSc11－17）. 
This finding may be dependent on the therapeutic 
status of SSc in this study.  Eight of the ten SSc 
patients were administered glucocorticoids for 
medication.  However, other immunopathological 
parameters such as ANA, Ig G and sIL-2R showed 
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significantly higher values. It is possible that levels 
of sCD40L fluctuated in response to the degree of 
disease activity.  However, higher numbers of SSc 
patients should be examined with respect to disease 
activities reported previously11－17）.
   The statistical analysis indicated that ANA 
is  the  only  candidate  for  the  detect ion of 
immunopathological alteration in SIL without any 
clinical manifestation of autoimmune disorders. 
However, in order to determine early subclinical 
markers for immunopathological status in SIL, 
the correlations between these parameters and 
hypothetical immunopathological progression 
status were assayed, using HD as 1, SIL as 2, and 
SSc as 3.  These results are presented in Fig. 2 
and show that serum levels of ANA and sIL-2R 
exhibited significant positive correlations with 
disease status, whereas levels of Ig G and sCD40L 
showed no such correlation.  These findings 
indicate that levels of ANA and sIL-2R were the 
only good markers of autoimmune dysfunction in 
SIL, although factor analysis showed that sCD40L 
formed an immunological factor with other 
immunopathological parameters, including sIL-2R.
DISCUSSION
   In order to analyze immunopathological 
dysfunction in SIL, it is important to consider the 
preclinical status of autoimmune disorders such as 
SSc and SLE１, ２）.  Reports of alterations in Fas and 
Fig. 1. Analysis of statistical differences between index values of serum titers of anti nuclear antibodies analyzed using the 
Enzyme-Linked ImmunoSorbent Assay (ELISA)-based MESACUP ANA Test Kit (MBL Co. Ltd., Nagoya, Japan),  serum 
immunoglobulin (Ig) G level, serum soluble interleukin (IL)-2 receptor (sIL-2R) level analyzed by ELISA (MBL), and serum 
soluble CD40 ligand (sCD490L) level assayed by ELISA (MBL) among healthy donors (HD), silicosis patients (SLI) and patients 
with systemic sclerosis (SSc).  Statistical significance was examined using the Mann-Whitney test.  Values of p ≤ 0.5 are shown 
in the figure.
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related molecules have been compared with similar 
observations found in autoimmune diseases19－28）, 
and it has been concluded that the dysfunction of 
autoimmunity and cellular and molecular processes 
caused by silica is similar in SIL and generalized 
autoimmune diseases１,２,６,７）.  In addition, our 
group revealed the reduced function of CD4+25+ 
peripheral T cells, in which regulatory T (Treg) cells 
are included41）.  Treg cells are known to possess the 
expression of a lineage-specific gene, FoxP3, and 
are important for control of the activation status 
of effector T cells.  If there is interference with 
the size and function of Treg, the T cell reaction 
against foreign and self antigens will be over-
activated and causes allergies and autoimmune 
disorders.  In contrast, if the size and function of 
Treg are enhanced, tumor immunity, host defense 
against foreign microorganisms, and immunity to 
transplanted tissues may all be reduced42－44）.  Thus, 
it is reasonable that SIL showed reduced Treg 
function41）.
   In the search for clinical parameters useful for 
the detection of subclinical immunopathological 
disorders in SIL, our group has found many 
autoantibodies, alterations of Fas-related molecules, 
and sIL-2R８－10,18－22,40）.  In this study, a similar role 
for sCD40L was examined because sCD40L was 
detected as a marker of disease activity for SSc 
and other autoimmune diseases11－17）.  If sCD40L is 
bound to membrane CD40 on B cells, continuous 
production of antibodies against self-antigens 
may result even after cessation of the activation 
of effector T cells31－39）.  However, various issues 
were raised in this study.  Firstly, and contrary to 
Fig. 2. Correlations between levels of clinical parameters such as ANA, Ig G, sIL-2R and sCD40L and ranked 
immunopathological progression (HD as 1, SIL as 2, SSc as 3) were analyzed using Fisher's z transformation ranking test.  
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expectation, sCD40L levels in SSc were lower 
than those recorded in HD and SIL.  Although SSc 
patients included in this study were medicated 
with corticosteroids and exhibited stable disease 
activities, other parameters such as Ig G, ANA and 
sIL-2R were significantly higher than those of HD. 
It was shown that sCD40L is sensitive to disease 
activity; however, the significance of this finding is 
undermined by the fact that this study only included 
ten patients.  Thus, a prospective study in relation to 
disease activity should be performed with a higher 
number of SSc patients.
   The second issue raised by this study concerns the 
role of sCD40L as a subclinical immunopathological 
parameter in SIL.  Although factor analysis showed 
that sCD40L formed factor 2 with most of the other 
immunopathological parameters, there was no 
significant correlation when immune dysfunction 
was viewed as a progression from HD ranked as 1, 
SIL as 2, and SSc as 3.  Of course, no correlation 
between sCD40L and the progression ranking is 
dependent on the issue mentioned above, and SSc 
patients did not show a higher level of sCD40L 
compared to HD.
   The overall results support the conclusion that 
the sCD40L level is altered with the progression 
of immunological dysfunction in SIL, but at 
present it is not considered a clinical parameter for 
the detection of subclinical immunopathological 
alterations found in SIL.  Further studies should 
be performed to elucidate the role of sCD40L in 
autoimmune diseases such as SSc, and then its role 
in SIL should be re-analyzed.
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